- Home
- POR vs LEGN Comparison
POR vs LEGN Comparison
Compare POR & LEGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | POR | LEGN |
|---|---|---|
| Founded | 1889 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Electric Utilities: Central | Biotechnology: Pharmaceutical Preparations |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.4B | 5.9B |
| IPO Year | N/A | 2020 |
Fundamental Metrics
Financial Performance| Metric | POR | LEGN |
|---|---|---|
| Price | $49.13 | $21.35 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 12 | 13 |
| Target Price | $46.33 | ★ $69.58 |
| AVG Volume (30 Days) | 1.1M | ★ 2.6M |
| Earning Date | 10-31-2025 | 11-12-2025 |
| Dividend Yield | ★ 4.29% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 2.78 | N/A |
| Revenue | ★ $3,511,000,000.00 | $909,045,000.00 |
| Revenue This Year | $5.15 | $68.83 |
| Revenue Next Year | $4.73 | $51.27 |
| P/E Ratio | $17.64 | ★ N/A |
| Revenue Growth | 5.09 | ★ 74.75 |
| 52 Week Low | $39.55 | $21.19 |
| 52 Week High | $51.14 | $45.30 |
Technical Indicators
Market Signals| Indicator | POR | LEGN |
|---|---|---|
| Relative Strength Index (RSI) | 54.19 | 19.54 |
| Support Level | $48.14 | $26.43 |
| Resistance Level | $49.43 | $28.97 |
| Average True Range (ATR) | 0.77 | 1.27 |
| MACD | -0.13 | -0.37 |
| Stochastic Oscillator | 48.40 | 1.22 |
Price Performance
Historical ComparisonAbout POR Portland General Electric Co
Portland General Electric is a regulated electric utility providing generation, transmission, and distribution services in a service territory that includes about half of all Oregon residents and two-thirds of the state's business activity. The company owns (wholly or through joint ventures) 3.5 gigawatts of gas, coal, wind, and hydro generation along with 300 megawatts of energy storage.
About LEGN Legend Biotech Corporation
Legend Biotech Corp is a clinical-stage biopharmaceutical company. It is engaged in the discovery and development of novel cell therapies for oncology and other indications. The firm's product candidate, LCAR-B38M/JNJ-4528, is a chimeric antigen receptor, or CAR, T cell therapy for the treatment of multiple myeloma. Geographically, the company generates a majority of its revenue from the United States of America. The company generates revenue from License and Collaboration revenue.